| Manufacturing |
|
| The Upcoming API Facility |
| With a view to ensure purity of our raw materials and by way of back ward integration to increase profits, 'ALVES' is in the process of setting up a facility for manufacturing and supplying Intermediates for manufacturing the API as per the regulatory norms and Active Pharmaceutical Ingredients for it's own consumption and as well as to customer's all over the world having USFDA, MHRA approved plants. |
| As there is enormous potential in a growing market of Intermediates and API's , promoter of the group is planning to have set up of reactors which can purify the material as per the regulatory norms to meet the impurity profile of unknown impurity less than 0.1% and if it is more than that, a facility for its characterization would be provided. The API/Intermediates would be purified and the impurity profiling of EP/Bp-2008 met and the manufacturing services for Intermediates/API would be provided to the customer by adhering strictly to the Quality norms of USFDA and MHRA |
 |
|
| The promoter is of the view that this business will grow substantially to mark a global presence in the pharmaceutical industry, with upcoming new product process development and to produce Multipurpose product without campaign basis. The present plant structure has already been modified in accordance therewith and authentication of STATE FOOD & DRUG ADMINISTRATIVE AUTHORITIES has been received. |
| Further the R&D department is developing the process which are not hazardous i.e. not at the purification stage as well as at the time of manufacturing too. |
| |
 |
| The reaction capabilities developed are:- |
- Grignard reaction.
- Organo phosphorous chemistry.
- Handling of the hazardous chemicals like chlorine, bromine, sodium, metal hydride, sodium cyanide, phosphorous etc.
|
| |
|
|
| R&D team for developing the nonhazardous process is been headed by doctors and is supported by team of 7 junior scientist. |
| |
| |
